Targeting leukemic stem and progenitor cells expressing different BCR::ABL1 levels: antileukemic activity of asciminib with or without TKIs. - Massimino M; Tirrò E; Romano C; Stella S; Tomarchio C; Vitale SR; Manzella L; Di Raimondo F; Stagno F; Vigneri P (Frontiers in pharmacology, 2026)